PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER

• Auteurs principaux: N. A. Avksentyev (Auteur), M. V. Zhuravleva (Auteur), E. M. Pazukhina (Auteur), A. V. Snegovoy (Auteur), M. Yu. Frolov (Auteur)
• Format: Livre
• Publié: ABV-press, 2018-08-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Background. Breast cancer is the most common malignant tumor and accounts for the most number of cancer-related deaths among Russian women. Combination of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor ribociclib and aromatase inhibitor is approved for the first-line treatment of postmenopausal...